ValuEngine upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research note issued to investors on Monday, February 4th.
Several other research firms have also weighed in on KRYS. HC Wainwright lifted their target price on Krystal Biotech from $32.00 to $35.50 and gave the stock a buy rating in a report on Monday, October 15th. Zacks Investment Research downgraded Krystal Biotech from a buy rating to a hold rating in a research report on Friday, January 4th. Cantor Fitzgerald reaffirmed a buy rating and issued a $34.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 19th. William Blair reissued a buy rating on shares of Krystal Biotech in a research report on Monday, November 5th. Finally, Cowen began coverage on Krystal Biotech in a research report on Wednesday, December 12th. They issued an outperform rating on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $33.40.
NASDAQ:KRYS opened at $22.75 on Monday. The firm has a market capitalization of $328.28 million, a PE ratio of -15.37 and a beta of 0.64. Krystal Biotech has a 12-month low of $8.91 and a 12-month high of $28.75.
Several hedge funds have recently modified their holdings of the stock. FMR LLC lifted its stake in Krystal Biotech by 32.1% during the fourth quarter. FMR LLC now owns 1,235,400 shares of the company’s stock worth $25,672,000 after purchasing an additional 300,000 shares during the last quarter. Great Point Partners LLC bought a new stake in Krystal Biotech during the fourth quarter worth $10,226,000. Barclays PLC bought a new stake in Krystal Biotech during the fourth quarter worth $777,000. Sphera Funds Management LTD. bought a new stake in Krystal Biotech during the fourth quarter worth $3,629,000. Finally, Geode Capital Management LLC lifted its stake in Krystal Biotech by 66.2% during the fourth quarter. Geode Capital Management LLC now owns 60,603 shares of the company’s stock worth $1,259,000 after purchasing an additional 24,137 shares during the last quarter. Institutional investors and hedge funds own 22.22% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: What is Cost of Debt?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.